Last Updated: June 26, 2026

Patent: 10,233,242

✉ Email this page to a colleague

Summary for Patent: 10,233,242

Title:	CTLA4 fusion proteins for the treatment of diabetes
Abstract:	A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.
Inventor(s):	Orban; Tihamer (Brookline, MA)
Assignee:	DMNOMORE (London, GB)
Application Number:	14/576,990
Patent Claims:	see list of patent claims

Details for Patent 10,233,242

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	December 23, 2005	⤷ Start Trial	2034-12-19
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	July 29, 2011	⤷ Start Trial	2034-12-19
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	June 07, 2016	⤷ Start Trial	2034-12-19
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	March 30, 2017	⤷ Start Trial	2034-12-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.